Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ADC Therapeutics SA - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
ADCT
New York
2836
www.adctherapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ADC Therapeutics SA
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
- Aug 6th, 2026 7:50 am
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
- Aug 6th, 2026 5:30 am
Alkermes (ALKS) Reports Break-Even Earnings for Q2
- Jul 28th, 2026 6:15 am
The Cancer Therapy Strategy VERAXA Is Betting the Company On
- Jul 6th, 2026 10:00 am
ADC Therapeutics Announces New Employee Inducement Grant
- Jul 1st, 2026 2:05 pm
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
- Jun 30th, 2026 5:15 am
ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Analyst Views
- Jun 27th, 2026 3:08 am
ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details
- Jun 24th, 2026 7:13 am
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
- Jun 24th, 2026 5:30 am
ADC Therapeutics (ADCT) Is Down 69.7% After Mixed LOTIS-5 ZYNLONTA Data - Has The Bull Case Changed?
- Jun 7th, 2026 6:17 pm
Top Midday Decliners
- Jun 4th, 2026 12:25 pm
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
- Jun 4th, 2026 8:43 am
An ADC specialist sinks on safety concerns for blood cancer drug
- Jun 4th, 2026 3:27 am
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Jun 3rd, 2026 2:05 pm
Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
- May 14th, 2026 7:20 am
ADC Therapeutics (ADCT) Q4 2025 Earnings Call Transcript
- May 4th, 2026 5:05 pm
ADC Therapeutics S.A. Q1 2026 Earnings Call Summary
- May 4th, 2026 2:44 pm
ADCT Q1 2026 Earnings Call Transcript
- May 4th, 2026 2:23 pm
ADC Therapeutics Q1 Earnings Call Highlights
- May 4th, 2026 7:39 am
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates
- May 4th, 2026 6:35 am
Scroll